Parallel Advisors LLC Has $2.50 Million Holdings in Novartis AG $NVS

Parallel Advisors LLC raised its position in Novartis AG (NYSE:NVS) by 29.6% during the first quarter, according to its most recent filing with the SEC. The firm owned 16,366 shares of the company’s stock after purchasing an additional 3,742 shares during the period. Parallel Advisors LLC’s holdings in Novartis were worth $2,500,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of the company. Morgan Stanley increased its position in shares of Novartis by 14.9% during the fourth quarter. Morgan Stanley now owns 8,876,906 shares of the company’s stock worth $1,223,860,000 after buying an additional 1,148,033 shares during the period. Fisher Asset Management LLC boosted its position in Novartis by 3.1% during the fourth quarter. Fisher Asset Management LLC now owns 7,465,850 shares of the company’s stock valued at $1,029,317,000 after acquiring an additional 226,484 shares during the last quarter. Auto Owners Insurance Co boosted its position in Novartis by 13,687.0% during the fourth quarter. Auto Owners Insurance Co now owns 4,628,296 shares of the company’s stock valued at $638,103,000 after acquiring an additional 4,594,726 shares during the last quarter. Bank of America Corp DE grew its holdings in Novartis by 1.7% during the 3rd quarter. Bank of America Corp DE now owns 4,605,878 shares of the company’s stock worth $590,658,000 after acquiring an additional 78,390 shares during the period. Finally, Franklin Resources Inc. grew its holdings in Novartis by 10.3% during the 4th quarter. Franklin Resources Inc. now owns 4,479,307 shares of the company’s stock worth $617,562,000 after acquiring an additional 419,988 shares during the period. 13.12% of the stock is owned by institutional investors.

Key Headlines Impacting Novartis

Here are the key news stories impacting Novartis this week:

• Positive Sentiment: Novartis topped Q2 earnings estimates, posting $2.41 per share versus $2.17 expected, while revenue also came in above forecasts. The beat was driven by strong demand for key drugs and lower-than-expected costs. Novartis earnings report
• Positive Sentiment: The company returned to sales growth in Q2 as newer medicines offset generic pressure, with strength in cancer and multiple sclerosis treatments helping support results. Reuters Q2 profit story
• Positive Sentiment: Management reaffirmed full-year 2026 guidance, which suggests confidence that growth from newer products can continue despite headwinds. Zacks earnings recap
• Neutral Sentiment: Investors are also watching upcoming late-stage trial readouts in the second half of the year, which could influence the stock’s longer-term valuation narrative. Reuters pipeline valuation story
• Negative Sentiment: Ongoing generic competition and a sharp drop in Entresto sales remain major headwinds, and investors may worry about pressure on older blockbusters. Invezz Entresto sales drop story

Wall Street Analyst Weigh In

NVS has been the topic of a number of recent analyst reports. Morgan Stanley boosted their price objective on Novartis from $143.00 to $170.00 and gave the company an “overweight” rating in a research note on Thursday, March 26th. Weiss Ratings downgraded Novartis from a “buy (a-)” rating to a “buy (b)” rating in a report on Wednesday, April 29th. Seven analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $141.20.

Novartis Trading Up 2.8%

NYSE:NVS opened at $153.82 on Wednesday. The company has a current ratio of 0.85, a quick ratio of 0.65 and a debt-to-equity ratio of 0.96. The stock has a market capitalization of $293.51 billion, a price-to-earnings ratio of 22.04, a PEG ratio of 2.58 and a beta of 0.45. The firm has a fifty day simple moving average of $151.61 and a two-hundred day simple moving average of $151.88. Novartis AG has a 12 month low of $112.34 and a 12 month high of $170.46.

Novartis (NYSE:NVS) last announced its quarterly earnings data on Tuesday, June 30th. The company reported $2.41 earnings per share for the quarter. The firm had revenue of $14.95 billion for the quarter. Novartis had a net margin of 24.87% and a return on equity of 38.82%. Analysts expect that Novartis AG will post 8.75 EPS for the current fiscal year.

Novartis Company Profile

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.